Material Transfer Agreements in Research Collaborations

Q: Do I need an MTA if the material is free or already published?

Usually yes. Even free or published materials are transferred under an agreement, because the MTA governs ownership, permitted use, and liability rather than price. Materials distributed at no charge, such as stem cell lines, still require a signed agreement.

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-11-11

Material Transfer Agreements in Research Collaborations

By the end of this article you will be able to explain what a material transfer agreement (MTA) does, read one clause by clause, draft a term sheet your technology transfer office can act on, send a material request that gets answered, and track a negotiation to signature without stalling your project. You will need three things on hand before you start: your institution's standard MTA template and the provider's template if you have it, the contact information for your technology transfer or research contracts office, and, for human biological materials, the informed consent documents or acquisition records for the original samples.

Most working scientists meet their first MTA as an obstacle between them and a vial, a cell line, or a dataset they already need. The agreement itself is not the obstacle. A poorly handled MTA is. Researchers in a qualitative study of biobanking practice in Uganda described MTAs as legal documents that define the obligations of each party during a study, and they linked successful agreements to ethical and legal rigor, multidisciplinary teams, and transparency [1]. This article turns those principles into a process you can follow.

What a Material Transfer Agreement Actually Is

A material transfer agreement is a legally binding contract between two organizations that governs the transfer of research materials from one to the other. The sending institution is usually called the provider. The receiving institution is the recipient. The agreement defines who owns the material, what the recipient may do with it, who controls any intellectual property that comes out of the work, how results can be published, and what happens to the material and its derivatives when the project ends.

The phrase "research materials" covers far more than most new scientists expect. Common examples include:

Cell lines, including stem cell lines. The Vrije Universiteit Brussel distributes fifteen human embryonic stem cell lines derived from surplus in vitro fertilization embryos and embryos carrying monogenic disorders, and those lines are available to other laboratories only after signing an MTA with the university [2]
Human biospecimens such as blood, tissue, and derived cell or DNA preparations
Plasmids, antibodies, viral vectors, and model organisms
Small molecules and drug candidates
Engineered biological constructs
Nonbiological research outputs such as datasets, software, and optimized methods. A high-resolution cardiac imaging sequence developed for contrast-free scar visualization is the kind of technical material that institutions may attach transfer terms to when it moves between sites [3]

The physical sample is rarely the whole story. An MTA also governs progeny (unmodified descendants of the material such as daughter cells), derivatives (modified forms such as purified fractions or transfected lines), and modifications the recipient creates. Getting these definitions right at the start prevents most later disputes.

Why MTAs Decide Whether a Collaboration Succeeds

Scientific collaboration depends on trust, but trust needs paperwork when public funding, human specimens, and intellectual property are involved. The Ugandan study of researchers involved in biobanking research identified four themes: the importance of MTAs, the facilitators of successful development and execution, the negotiation of power dynamics between institutions during drafting, and the barriers to drafting and execution [1]. Researchers in that study saw MTAs as the instrument that makes each party's obligations explicit rather than assumed.

The need is not theoretical. A retrospective review of 200 research protocols submitted to the Medical Research Council of Zimbabwe between 2009 and 2016, all involving human biospecimen collection, biobanking, or genomic research, found that consent practices varied widely. Of those protocols, 99 (49.5 percent) used specific consent, 37 (18.5 percent) used broad consent, and 37 (18.5 percent) used blanket consent, while 2 (1 percent) used no consent forms at all. Only 44 (22 percent) included plans for destroying collected samples, and 44 (22 percent) involved exporting biospecimens [4]. Every one of those gaps becomes a concrete problem when material crosses an institutional or national border under an MTA. If the original consent does not permit the transfer, or if nobody documented what happens to samples at the end of the study, the agreement cannot be drafted cleanly.

Understanding the MTA process is therefore a research skill, in the same category as experimental design or statistical literacy. The Ugandan researchers found that limited understanding and limited experience with MTA processes were themselves barriers, alongside protracted bureaucratic approval steps [1]. This article addresses both by walking through the process and the paperwork.

The Clauses That Matter Most

Every MTA is different, but the core clauses recur. Use the table below as your review map. Your technology transfer office owns the legal judgment on each one, but you own the scientific judgment on what the language means for your experiments.

Clause	What it controls	What you personally check
Definition of Material	Exactly what was and was not transferred	Does the list match the actual vials, files, or constructs shipped
Permitted Use	The research purposes allowed	Does it cover every aim in your funded grant
Ownership and Title	Who retains the material and progeny	Whether your institution gains any rights to unmodified material
Intellectual Property	Who owns discoveries and inventions	Whether your aims could produce patentable results
Publication	Rights and delays before publishing	Whether students can still submit theses on time
Redistribution	Passing material to third parties	Whether your named collaborators count as third parties
Confidentiality	What information stays private	Whether it blocks discussion with your usual seminar circle
Liability	Responsibility for harm or misuse	Which party carries risk if the material misbehaves
Termination	Return, destruction, or retention at project end	Whether you can afford to destroy irreplaceable controls
Compliance	Regulatory and ethical requirements	Ethics approvals, permits, and consent scope for human materials

Material Transfer Agreement Research Collaboration Step by Step

This walkthrough follows the sequence most institutions actually use. Each step lists the action, the output, and the failure mode to watch for.

Step 1: Establish provenance before you request anything

Provenance means the documented history of the material, including where it came from and under what permissions. For human biological material, the original consent scope is the foundation. The Zimbabwean protocol review showed how much consent scope varies between studies, from specific consent to broad and blanket consent, and how rarely sample destruction was planned [4]. Before you email anyone, ask the provider three questions: what consent covers the material, whether that consent permits transfer to your institution and to your planned uses, and what documentation exists. If the answers are unclear, resolve that first. An MTA built on consent that does not cover the intended use will fail later, sometimes after you have published.

Step 2: Send a request that a contracts office can act on

Vague requests are the main reason transfers stall. Send one email to the provider's technology transfer or research contracts office, copied to the collaborating scientist, that names the material, the purpose, the funder, and your willingness to sign their template.

Subject: MTA request, [material name], [your lab], [your institution]

Dear [contact name] and the [institution] technology transfer office,

Our laboratory at [your institution] would like to request
[exact material name and identifier] for use in [one-sentence
project description]. The work is funded by [grant or fund name]
and led by [principal investigator name].

We are prepared to sign your standard material transfer agreement.
Could you please send the template and confirm:

1. Shipping address and any permits required for the transfer
2. Handling and storage conditions we must follow on receipt
3. Whether you require our institutional template instead of yours

Thank you,
[Name, title, department, institution, phone]

The expected reply is either the provider's MTA template, a request for your institutional template, or a clarification question. Any of those three counts as progress. Silence after two weeks means you follow up with the collaborating scientist, not the contracts office, because scientists respond to scientists.

Step 3: Choose the template and the route

Many institutions maintain a standardized master agreement for biological materials so that routine transfers do not require bespoke negotiation each time. If both institutions have such a template, the negotiation usually reduces to a small number of fill-in fields. If the provider sends a bespoke agreement, expect a longer review. Either way, the review runs through your own technology transfer office. Never sign, or let a supervisor sign, on behalf of the institution. Individual scientists have no authority to bind their employer.

Step 4: Review clause by clause with a checklist

Read the agreement against a fixed checklist so that nothing depends on memory or mood.

MTA REVIEW CHECKLIST
[ ] Parties named with full legal entity names
[ ] Definition of Original Material matches the shipping list
[ ] Progeny, derivatives, and modifications are assigned
[ ] Permitted Use covers every aim in the funded project
[ ] Publication terms allow theses, preprints, and conference talks
[ ] Intellectual property terms reviewed by tech transfer office
[ ] Redistribution to third parties requires written consent
[ ] Liability and indemnification reviewed by legal counsel
[ ] Termination, return, or destruction requirements are workable
[ ] Effective date and authorized signatures are correct

Two clauses deserve your closest personal attention. Permitted Use is where collaborations break. If your grant says you will test the material in three disease models and the agreement says "for theRecipient's internal research purposes only," you have a problem you want to find before signature, not at year two. Publication is the other. A clause that lets the provider delay or veto manuscripts can collide with student graduation dates and funder requirements, so flag any publication delay longer than about 30 days for negotiation.

Step 5: Negotiate in writing with a tracking sheet

Keep a simple spreadsheet of every open point. It prevents the most common negotiation failure, which is losing track of who agreed to what.

Clause,Our position,Provider position,Status,Owner,Next action
Permitted use,"All funded aims incl. xenograft work","Internal research only",Counter sent,You,Await reply by June 3
Publication delay,30 days,90 days,Counter proposed,You,Counteroffer in revision
Shipping cost,Provider pays,Recipient pays,Agreed 50/50,Both,Confirm in redline

When you open a redlined document, make one revision per point and state your reason in a comment. Counteroffers like "30 days rather than 90 days for preprint review, all other publication terms accepted" resolve faster than wholesale rewrites, because they show the other office exactly which issues remain.

Step 6: Execute the agreement correctly

Execution means signatures from authorized institutional signatories at both organizations, with the effective date filled in. Check that the signatory is the contracts officer, not the scientist. Check that the name of the receiving principal investigator, the material description, and the permitted use statements match the final negotiated text. A mismatch between the signed definition of Material and the actual shipment is a common and avoidable defect, so compare the agreement's material list to the packing list line by line before the box ships.

Step 7: Manage the material under the terms

Once the material arrives, the agreement is live. Record the receipt date, storage location, and lot or passage number in a laboratory inventory system. Follow the handling conditions. This matters even for materials that seem robust. In a study standardizing offline breath sampling, factors as basic as tubing material, collection bag composition, and transfer flow rate measurably affected volatile organic compound results, which is exactly why transfer documents should specify handling conditions rather than leave them to custom [5]. Keep the reporting obligations from the agreement, such as annual brief reports, on your calendar. An unreported milestone is an easy way to sour a provider relationship.

Step 8: Close out when the project ends

Most agreements require the recipient to destroy or return the remaining material and sometimes to certify destruction in writing. Do this on schedule, send the certification, and archive the signed agreement where your institution requires it. If your research produced derivatives you want to keep, that requires a written amendment, not a quiet decision to keep a freezer box.

Material Transfer Agreement Research Collaboration Tips

Researchers who have managed these agreements repeatedly converge on a few practices, several of which match the facilitators identified in the Ugandan biobanking study: robust ethical and legal frameworks, multidisciplinary teams, and transparency [1]. Put into daily practice, they look like this.

Start the MTA before you need the material. Protracted bureaucratic approval was reported as a barrier in the Ugandan study [1]. Build one to three months of contract time into your project plan for a standard transfer and more for a bespoke one.

Form a small team around each agreement. The Ugandan researchers credited multidisciplinary teams for successful execution [1]. In practice that means the scientist who knows the experiment, the contracts officer who knows the clauses, and, for human materials, an ethics or regulatory colleague who can confirm consent scope.

Be transparent about intent. Providers worry most about unknown uses. Stating your aims, funder, and publication plans up front shortens negotiation because it answers the questions the provider's office would otherwise ask one email at a time.

Respect the power dynamic, and plan for it. The Ugandan study identified power dynamics between institutions as a distinct theme in drafting [1]. When a large hospital system negotiates with a small university, or a well-funded provider negotiates with a resource-limited recipient, the weaker party often accepts terms it has not fully examined. If you are on the weaker side, your protection is process: insist that your contracts office reviews every clause, and never accept verbal assurances about what a clause "really means."

Learn one agreement deeply. Reading your institution's standard template once, carefully, teaches you the vocabulary you will meet in every future negotiation. Twenty minutes of reading prevents years of deferring entirely to counsel on decisions that have scientific consequences.

Common Mistakes and Limitations

These are the errors that most often damage collaborations, drawn from the recurring failure points in the literature and from standard institutional practice.

Treating a friendly email as permission. A colleague saying "sure, send you some cells" is not an MTA. The transfer still needs a signed agreement between the institutions, and materials moved informally can create liability for both parties.
Assuming consent transfers with the sample. The Zimbabwean protocol review found that consent types varied across studies and that only a minority of protocols had sample destruction plans [4]. If the original consent does not cover your intended use or your institution, no MTA can fix that retroactively.
Redistributing to a collaborator without written consent. Most MTAs prohibit passing the material to third parties, and a named co-investigator at another university is usually a third party. Request an amendment instead.
Ignoring progeny and derivatives. Scientists are often surprised that daughter cell lines or purified fractions fall under the agreement. Ask your contracts office how the definitions apply to your planned experiments before you create them.
Letting publication clauses collide with student timelines. A 90-day provider review period can push a thesis defense past a graduation deadline. Negotiate these terms before signature, when you have leverage.
Underestimating timelines and losing goodwill. Protracted approvals frustrate everyone, but responding by cutting corners creates larger risks [1]. A realistic schedule with a named person chasing each step keeps the collaboration warm.
Losing institutional memory. When the postdoc who negotiated the agreement leaves, the tracking spreadsheet is what preserves the record. Store executed agreements and redlines in your institution's contract repository, not in a personal inbox.

A final limitation worth stating plainly: this article explains process and clause logic, not legal advice. Individual agreements, especially those involving human specimens, controlled materials, or commercial partners, need review by your institution's legal and compliance professionals.

Tools That Keep the Process Moving

Material transfer work sits inside the larger machinery of scientific collaboration, and the tools that help are usually unglamorous. A shared spreadsheet with the negotiation tracker shown above is often sufficient. Institutional contract management systems track versions and signatures. E-signature platforms shorten execution from weeks to days. For research teams handling complex collaborations, structured processes help in other ways too. A recent international consensus project on living evidence synthesis in health care ran three modified Delphi rounds with 29 experts through an online survey platform to agree on 23 methodological statements [6], an example of how structured rounds and clear consensus thresholds keep multi-institution groups moving. In the same spirit, co-produced guidance on patient and public involvement in doctoral research was built through iterative discussion and revision among doctoral researchers, public contributors, and a coordinator [7], which mirrors how a good MTA negotiation works: written positions, visible revisions, and a shared record.

The Ugandan researchers in the biobanking study organized their qualitative data with NVivo 12 software [1], a reminder that even the research about research agreements benefits from disciplined tooling. The specific tool matters less than the habit. Choose one system for agreement documents, one for the negotiation log, and one for material inventory, and use them consistently.

Frequently Asked Questions

Do I need an MTA if the material is free or already published?

Usually yes. Even materials described in a published paper or offered at no cost are transferred under an agreement, because the agreement governs ownership, use, and liability rather than price. Cell lines distributed at no charge still require a signed MTA, as the example of the VUB stem cell lines shows [2].

Who signs the MTA, the scientist or the institution?

The institution signs. Only an authorized institutional signatory, typically in the technology transfer or research contracts office, can bind your organization. Scientists may be named as the receiving investigator, but their signature alone has no contractual force.

How long does an MTA take to execute?

There is no fixed duration, but delays are common enough that researchers in the Ugandan study named protracted bureaucratic approval as a barrier [1]. Plan several weeks for a standard template and longer for a bespoke agreement, and start the request before you need the material.

What is the difference between an MTA and a data use agreement?

An MTA governs physical or tangible research materials such as cells, specimens, and constructs. A data use agreement governs the transfer and permitted analysis of data. Large collaborations often need both, and the two documents must agree on permitted use so the terms do not contradict each other.

Can I share the material with my collaborator at another university?

Not without written permission. Most agreements define any third-party transfer as redistribution, which requires an amendment or a separate agreement between the original provider and your collaborator. Ask early, because that second agreement takes time.

What happens to leftover material when the project ends?

The agreement's termination clause controls it. Typical requirements are to destroy or return the remaining material and certify destruction in writing. If you want to retain derivatives, negotiate a written amendment rather than keeping material informally.

Do MTAs cover publications and patents?

Yes. Publication clauses set review periods and confidentiality limits around manuscripts, and intellectual property clauses assign rights to discoveries and inventions arising from the material. Both clauses deserve clause-by-clause review before signature because they directly affect your students and your grant deliverables.

What should I do if the provider sends an agreement I do not understand?

Send it to your technology transfer office with a short list of the clauses that concern your science. Never rely on verbal assurances from the other side about what a clause means. Limited understanding of MTA processes is a recognized barrier, and your contracts office exists precisely to close that gap [1].